Newsroom

Host cells stained in blue with binding of LecA (green)
News
The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates. These optimized molecules have been tested in virulence assays and show promising properties for the development of new drugs.
16.01.2023
Symbolic image: Illustration of human cells
News
Würzburg, January 10, 2023 — Do we simply ingest a diagnostic probiotic based on programmed ribonucleic acids to analyze the intestinal health from individual cells in the future? Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have developed a new technology they call TIGER. It allows complex processes in individual cells to be deciphered in vivo by recording past RNA transcripts. The findings were published in the journal Nature Biotechnology on 5 January 2023.
10.01.2023
Portrait of Prof Gérard Krause
News
The 2022 Prize for Translational Infection Research of the German Center for Infection Research (DZIF), endowed with 5,000 euros, goes to the DZIF scientist and epidemiologist Gérard Krause, head of the department "Epidemiology" at the Helmholtz Centre for Infection Research (HZI) in Braunschweig. Prof Krause researches the spread and clinical consequences of infectious diseases in the population and develops methods for their prevention, diagnosis and epidemic control. He has now been honoured with the DZIF Prize for his outstanding contributions in the field of translational infection epidemiology and in particular for the development of the epidemic management system SORMAS.
09.01.2023
Prof. Dr. Chase Beisel and Dr. Oleg Dmytrenko.
News
It is an unexpected discovery by scientists at the Helmholtz Institute Würzburg in cooperation with Benson Hill, Inc. (Missouri) and Utah State University in the U.S.: They have found a nuclease, which they dubbed Cas12a2, that represents an entirely new type of CRISPR immune defense. Unlike any other previously known nuclease of the CRISPR-Cas immune system, the source of "gene scissors", Cas12a2 destroys DNA to shut down an infected cell. The findings could lead to new CRISPR technologies for molecular biology diagnostics, among other applications, and were published today in the journal Nature.
04.01.2023
Portrait
News
The lawyer Christian Scherf will start as Administrative Director at the Helmholtz Centre for Infection Research (HZI) in Braunschweig on 1 January 2023. The former Chancellor of the Berufliche Hochschule Hamburg succeeds Silke Tannapfel, who left the HZI at the end of 2021 to join the Hessian Ministry of Science and the Arts. The position of Administrative Director was temporarily taken over by Elisabeth Gerndt, authorised signatory and head of the Finance and Controlling Department, until 31 December 2022.
23.12.2022
Aktinzytoskelett einer migrierenden Zelle mit Zellkern
News
Bacterial pathogens like Salmonella, Shigella, Listeria and many others exploit the protein skeleton of the cells they infect in order to spread throughout the host. However, how is this so-called cytoskeleton of host cells assembled and remodelled? Answers to this question can provide new approaches for combatting the causative agents of infectious diseases. An international team of researchers including HZI-members have now unravelled precise molecular mechanisms of activation of a key signalling unit in cytoskeletal remodelling. These recent results have just appeared in Science Advances.
15.12.2022

HZI in the media

Quelle:

 

Pressemitteilung Helmholtz-Zentrum für Infektionsforschung HZI ...

10.12.2025
|
LaborPraxis

Medikament Tolcapon identifiziert. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation ...

01.12.2025
|
Homburg

... wissenschaftlicher Ko-Direktor des Helmholtz Zentrums für Infektionsforschung (HZI). Thomas Pietschmann engagiert sich seit 2023 im ...

28.11.2025
|
juraforum.de

Dr. Alexander Titz, group leader at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). “Finding new ways to disrupt its

28.11.2025
|
ARCHYDE

... “, sagte die Leiterin der Epidemiologie am Braunschweiger Helmholtz-Zentrum für Infektionsforschung.

 

Lange betonte, flächendeckende ...

28.11.2025
|
Evangelische Zeitung

... ein Zentrum für Quantentechnologie entstehen und das Helmholtz-Institut für Pharmazeutische Forschung ausgebaut werden.

 

Mehr ...

27.11.2025
|
Tagesschau

Euro werden investiert in die Erweiterung des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS). Und ...

27.11.2025
|
ZEIT online

s drug tolcapone. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

 

The

26.11.2025
|
Medical Xpress

... erhielt das Projekt „Citrapeutics“ vom Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig eine Förderung in Höhe ...

25.11.2025
|
Bionity.COM

led by Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI) has now discovered clear molecular signatures for

24.11.2025
|
Medical Xpress

Medizinischen Hochschule Hannover (MHH) und dem Helmholtz-Zentrum für Infektionsforschung (HZI), hat nun eindeutige molekulare Signaturen ...

24.11.2025
|
DeutschesGesundheitsPortal

Braunschweig. Das Helmholtz-Zentrum für Infektionsforschung (HZI) bringt anlässlich seines 60. Jubiläums seine Forschung vom 3. ...

22.11.2025
|
Regional Heute

Register now for the HZI-Newsletter